Tarsus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TARSUS, and when can generic versions of TARSUS drugs launch?
TARSUS has one approved drug.
There are six US patents protecting TARSUS drugs.
There are thirty-nine patent family members on TARSUS drugs in twenty-five countries and fifteen supplementary protection certificates in fifteen countries.
Summary for Tarsus
| International Patents: | 39 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Tarsus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | 8,383,659 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | 10,835,517 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | 11,690,826 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | 11,197,847 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | 11,752,137 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Tarsus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Netherlands | 300891 | ⤷ Try a Trial |
| Australia | 2009327079 | ⤷ Try a Trial |
| Russian Federation | 2518462 | ⤷ Try a Trial |
| Hungary | S1700034 | ⤷ Try a Trial |
| China | 111655241 | ⤷ Try a Trial |
| Russian Federation | 2020122841 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tarsus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2379537 | 122017000053 | Germany | ⤷ Try a Trial | PRODUCT NAME: LOTILANER; REGISTRATION NO/DATE: EU/2/17/206 20170425 |
| 2379537 | 40/2017 | Austria | ⤷ Try a Trial | PRODUCT NAME: LOTILANER UND SALZE DAVON; REGISTRATION NO/DATE: EU/2/17/206 (MITTEILUNG) 20170427 |
| 2379537 | 2017C/029 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CREDELIO - LOTINALER; AUTHORISATION NUMBER AND DATE: EU/2/17/206 20170427 |
| 2379537 | LUC00030 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LOTILANER ET SES SELS; AUTHORISATION NUMBER AND DATE: EU/2/17/206 20170427 |
| 2379537 | 132017000099235 | Italy | ⤷ Try a Trial | PRODUCT NAME: LOTILANER(CREDELIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/2/17/206, 20170427 |
| 2379537 | 300891 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LOTILANER EN ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/2/17/206 20170427 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
